An innovative Web-based resource called the NIH Pipeline to Partnerships or P2P has been inaugurated here today by the premiere internationally acclaimed funding organization National Institutes of Health, better known in the abbreviated form as the NIH. It has been averred by the NIH in this respect, that the main intention of the introduction of the new device is to expand the development of NIH's exclusive licensed technologies and technologies that are financed in the course of the NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs.

So what is the basic credibility of the new approach? It has been found rather form the discourses with the various echelons of the NIH that this new P2P project has been built up jointly as a distinguished collaborative effort undertaken by both the NIH Office of Technology Transfer (OTT) and the NIH SBIR and STTR Program Office.   The chief emphasis in this esteem has been conferred upon the provision of an essential space thorough which for the better perception of the target audience comprised of potential strategic partners, investors, and licensees the NIH licensees and NIH SBIR/STTR awardees can exhibit their technologies and product development. It is to be mentioned that in the recent years the NIH has been considerably engaged in the innovation of stable avenues so as to help the new-fangled biomedical technologies to succeed in due course and at one fell swoop in the promotion of the gradual development and thereby the sturdy entry into the souk.   

While talking to the newsmen over the latest approach of the NIH, Dr. Mark Rohrbaugh, J.D., Director of the NIH Technology Transfer Office said, "In the last decade, many successful biomedical products have come from pharmaceutical and biotechnology companies that licensed early-stage technologies from NIH." "Faced with less demand for early-stage technologies, this pipeline provides an avenue for potential partners to find NIH licensees along the spectrum of product development to share costs, infrastructure, and expertise as the research and development progresses to later stage clinical trials."

Again, from Jo Anne Goodnight, the Coordinator of NIH's SBIR/STTR programs, it has been learnt that the NIH P2P initiative is also able to help NIH SBIR/STTR awardees who have to cope with similar challenges while working on with their innovations all along the development pipeline. He said, "These small companies simply can't go it alone," said Jo Anne Goodnight, Coordinator of NIH's SBIR/STTR programs. "Given the expensive pre-clinical and clinical studies necessary to bring novel products to the market and the patient, many of these projects need additional financing, licensing deals, or strategic partnerships." "We see the P2P database as an important resource to help small businesses make a successful leap from discovery to commercialization of products resulting from innovative biomedical and behavioral research," he concluded.